X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What you should know: Government arbitration is the wrong way to change Medicare

By Juliet Johnson  |    June 10, 2019
As Washington looks to make changes to Medicare, there are right ways and wrong ways to address the challenges patients face. In recent weeks, policymakers have discussed imposing government...   Read More

PhRMA comments to administration on Medicare Part D proposed rule

By Juliet Johnson  |    January 25, 2019
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the CMS proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and...   Read More

New research shows changes to the six protected classes would harm most vulnerable patients and are unnecessary

By Juliet Johnson  |    January 24, 2019
In Medicare Part D, the six protected classes policy protects vulnerable seniors and low-income beneficiaries with serious and complex health conditions, while also allowing Part D insurance plans...   Read More

Keep the Six Protected Classes, protected

By Juliet Johnson  |    January 22, 2019
Medicare Part D has been successfully providing seniors with comprehensive drug coverage for more than a decade, and one of the cornerstones of the program has been to ensure the sickest and most...   Read More

4 things you need to know about the administration’s latest Part B proposal

By Nicole Longo  |    November 5, 2018
The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....   Read More

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

By Juliet Johnson  |    September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines.  These...   Read More

Pass-through rebates do not violate non-interference clause but they do increase savings for seniors

By Jim C. Stansel  |    July 2, 2018
For more than a decade, Medicare Part D has successfully provided seniors with comprehensive prescription drug coverage. Key to its success is a unique, market-based structure of private-sector...   Read More

Medicare Part D cliff ahead

By Juliet Johnson  |    June 21, 2018
Medicare Part D has been providing seniors with access to prescription drug coverage that meets their needs for more than a decade. Today, more than 42 million people are enrolled in Part D and 90...   Read More

Part D cliff looms for seniors, as program stability could be in jeopardy

By Juliet Johnson  |    June 18, 2018
For more than a decade, Medicare Part D has successfully provided seniors comprehensive prescription drug coverage that meets their needs, while its market-based structure has kept overall program...   Read More

New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D

By Juliet Johnson  |    May 9, 2018
Today, we are launching the “Let’s Talk About Medicare” advertising campaign focused on solutions to improve affordability and predictability for seniors in Medicare Part D. Similar to how the “...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates